Purchase this article with an account.
Mathias M Maier, Sophia Bonse, Christiane Frank, Nikolaus Feucht, Chris Lohmann; Jetrea (ocriplasmin) as a treatment option for symptomatic vitreomacular traction with or without macular hole (<400 µm) - first clinical experience. Invest. Ophthalmol. Vis. Sci. 2014;55(13):299.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the resolution rate after therapy with intravitreal Jetrea (ocriplasmin) in patients with symptomatic vitreomacular traction (<1500 µm) with or without macular hole (<400 µm) in a clinical setting.
Until now we prospectively examined 14 eyes of 14 patients with symptomatic vitreomacular traction with or without macular hole who underwent intravitreal injection of 0,1ml Jetrea. Visual acuity and SD-OCT ultrastructural parameters were measured before injection. Resolution of the vitreomacular traction, visual acuity and SD-OCT ultrastructural parameters were evaluated again one month after treatment in preliminary 8 of 14 treated eyes as a temporary outcome in the ongoing assessment.
Vitreomacular traction resolved in 6 of the 8 injected and yet evaluated eyes. 2 of them showed full-thickness macular hole afterwards. 2 eyes initially presented macular holes which both closed. Best corrected visual acuity was 0.46±0.28 Log MAR at baseline, improving to 0.36±0.21 Log MAR at 1 month after injection. Foveal thickness was 354,87±59,9 µm at baseline, reducing to 294±66,6 µm at 1 month.
In the ongoing study, there was yet a large percentage of resolution of vitreomacular traction and closure of macular holes after injection of Jetrea. This was further associated by an improvement of visual acuity and reduction of foveal thickness.
This PDF is available to Subscribers Only